Approved: Dissecting the Teva-Allergan merger
The Federal Trade Commission was quick to highlight that it had required global pharmaceutical giant Teva to unload 79 generic drugs — the largest drug divestiture in one of its cases...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login
to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information:
FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch